AmoyDx(300685)2022-04-20 16:00Financial Performance - The company's operating revenue for Q1 2022 was ¥206,049,845.51, representing an increase of 18.60% compared to ¥173,734,244.08 in the same period last year[6]. - Net profit attributable to shareholders for Q1 2022 was ¥53,614,836.90, up 23.46% from ¥43,427,819.49 in the previous year[6]. - The net profit after deducting non-recurring gains and losses was ¥49,077,254.65, reflecting a 25.82% increase from ¥39,006,740.62 year-on-year[6]. - Basic and diluted earnings per share for Q1 2022 were both ¥0.24, a 20.00% increase from ¥0.20 in the previous year[6]. - Total operating revenue for the first quarter reached ¥206,049,845.51, an increase of 18.5% compared to ¥173,734,244.08 in the previous year[34]. - Net profit for the period was ¥53,336,627.60, representing a 22.8% increase from ¥43,427,812.07 in the same quarter last year[36]. - Total comprehensive income for the period was CNY 53,336,627.60, compared to CNY 43,427,812.07 in the previous period, representing a growth of approximately 23.5%[40]. - Basic and diluted earnings per share increased to CNY 0.24 from CNY 0.20, reflecting a 20% increase[40]. Cash Flow - The net cash flow from operating activities decreased by 55.14% to ¥27,961,142.84, down from ¥62,324,682.53 in the same period last year[6]. - Cash inflow from operating activities was CNY 198,916,694.38, slightly down from CNY 200,900,983.53, indicating a decrease of about 1%[42]. - The company's total cash inflow from operating activities was CNY 198,916,694.38, while cash outflow was CNY 170,955,551.54, resulting in a net cash flow of CNY 27,961,142.84[42]. - Cash outflow for investing activities totaled CNY 107,925,200.78, down from CNY 341,804,650.87, a reduction of about 68%[47]. - Net cash flow from investing activities was negative at CNY -140,286.55, compared to CNY -45,331,843.78 in the previous period[47]. - Cash flow from financing activities resulted in a net outflow of CNY -17,034,520.27, compared to CNY -356,217.29 previously[47]. - The ending cash and cash equivalents balance was CNY 245,046,650.76, down from CNY 376,231,190.87, a decrease of approximately 34.8%[47]. - The company reported a decrease in cash received from investment recovery to CNY 105,000,000.00 from CNY 294,000,000.00, a decline of about 64.2%[46]. Assets and Liabilities - Total assets at the end of Q1 2022 were ¥1,535,133,046.49, a 1.00% increase from ¥1,519,881,333.25 at the end of the previous year[6]. - Total liabilities decreased to ¥124,170,461.08 from ¥150,250,223.95, a reduction of 17.4%[30]. - The company's equity attributable to shareholders rose to ¥1,406,060,373.19, up from ¥1,364,580,687.78, indicating a growth of 3.1%[33]. - The cash and cash equivalents increased to ¥1,212,452,945.83 from ¥1,196,020,727.99, reflecting a growth of 1.3%[33]. - The company reported a decrease in accounts payable from ¥24,021,136.22 to ¥16,276,754.19, a decline of 32.2%[30]. - The company’s deferred income tax assets increased to ¥21,056,557.57 from ¥20,457,300.33, showing a growth of 2.9%[33]. Shareholder Information - The total number of common shareholders at the end of the reporting period is 19,119[14]. - The largest shareholder, Forward Investment (Hong Kong) Limited, holds 21.97% of shares, totaling 48,723,120 shares[14]. - The total number of common shares held by the top ten shareholders accounts for a significant portion of the company's equity[14]. - The company has implemented a stock incentive plan, with a total of 2,123,700 restricted shares at the beginning of the period[21]. - The company has not identified any related party relationships among the top shareholders, except for a mother-daughter relationship between two of the shareholders[17]. Research and Development - Research and development expenses were ¥38,760,861.03, which is a 18.5% increase compared to ¥32,700,720.91 in the previous year[34]. - In January 2022, the PCR-11 gene product was included in Japan's medical insurance[22]. - In March 2022, the PD-L1 antibody reagent received approval from the National Medical Products Administration[22]. Expenses - Sales expenses for Q1 2022 were ¥61,722,822.00, an increase of 42.82% compared to ¥43,217,128.57 in the same period last year[10]. - Total operating costs amounted to ¥151,509,513.28, up from ¥125,941,512.78, reflecting a year-over-year increase of 20.4%[34]. - Investment income for Q1 2022 was ¥1,774,558.80, a significant increase of 210.40% from ¥571,701.45 in the previous year[13]. - The net cash flow from investing activities improved by 99.69%, with a net outflow of ¥140,286.55 compared to a much larger outflow of ¥45,331,843.78 in the same period last year[13].